DOCSLIB.ORG

The Annual Report of the State of the National Vaccine Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Annual Report of the State of the National Vaccine Plan THE ANNUAL REPORT OF THE STATE OF THE NATIONAL VACCINE PLAN U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 2014 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES TABLE OF CONTENTS ACRONYMS AND ABBREVIATIONS ....................................................................................................................................................................................................3 DIRECTOR’S NOTE ......................................................................................................................................................................................................................................6 REPORT INTRODUCTION.........................................................................................................................................................................................................................8 TABLE 1: THE 2010 NATIONAL VACCINE PLAN RESPONSIBLE STAKEHOLDERS ........................................................................................................11 GOAL 1: DEVELOP NEW AND IMPROVED VACCINES ..............................................................................................................................................................12 DISCOVERY AND CREATION OF NEW VACCINES .................................................................................................................................................................... 13 OPTIMIZING VACCINE PREPARATION, USE AND DELIVERY .............................................................................................................................................. 24 SEASONAL INFLUENZA PREVENTION AND PANDEMIC PREPAREDNESS ..................................................................................................................30 GOAL 2: ENHANCE THE VACCINE SAFETY SYSTEM .............................................................................................................................................................. 35 ADVANCING VACCINE SAFETY SYSTEMS ................................................................................................................................................................................... 36 PROGRESSING VACCINE SAFETY RESEARCH ........................................................................................................................................................................... 48 GOAL 3: SUPPORT COMMUNICATIONS TO ENHANCE INFORMED VACCINE DECISION-MAKING ................................................................... 51 FOSTERING COLLABORATION TO COMBAT HPV INFECTION ...........................................................................................................................................52 COMMUNICATION SCIENCE APPROACHES TO IMPROVE DECISION-MAKING AND ACCEPTANCE ............................................................... 58 OTHER SELECTED VACCINE COMMUNICATION EFFORTS ................................................................................................................................................. 63 GOAL 4: ENSURE A STABLE SUPPLY OF, ACCESS TO, AND BETTER USE OF RECOMMENDED VACCINES IN THE UNITED STATES ...........................................................................................................................................64 EXPANDING ACCESS TO VACCINES .............................................................................................................................................................................................. 65 PRIORITIZING ADULT IMMUNIZATION ........................................................................................................................................................................................... 68 INTEGRATING IT SYSTMES FOR IMPROVED IMFORMATION SHARING ......................................................................................................................... 70 OTHER SELECTED ADVANCES IN VACCINE SUPPLY, ACCESS AND USE .................................................................................................................... 76 GOAL 5: INCREASE GLOBAL PREVENTION OF DEATH AND DISEASE THROUGH SAFE AND EFFECTIVE VACCINATION ..................77 REDUCING THE GLOBAL IMPACT OF DISEASE ......................................................................................................................................................................... 78 PROTECTING HEALTH AT HOME AND ABROAD ...................................................................................................................................................................... 87 OTHER SELECTED ADVANCES IN GLOBAL IMMUNIZATION .............................................................................................................................................. 92 APPENDIX 1: UPDATE ON THE NATIONAL VACCINE ADVISORY COMMITTEE ..........................................................................................................94 APPENDIX 2: PROGRESS ON THE IMPLEMENTATION OF THE NATIONAL VACCINE PLAN ...............................................................................101 APPENDIX 3: HEALTHY PEOPLE 2020 BACKGROUND OF IMMUNIZATION AND INFECTIOUS DISEASE GOALS .....................................114 APPENDIX 4: STAKEHOLDER WEBSITE GUIDE .........................................................................................................................................................................115 APPENDIX 5: INFORMATION AND RESOURCES FOR THE PUBLIC .................................................................................................................................. 117 STATE OF THE NATIONAL VACCINE PLAN 2014 2 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ACRONYMS AND ABBREVIATIONS ACV Advisory Commission on Childhood Vaccines ACF Administration for Children and Families ACIP Advisory Committee on Immunization Practices ACOG American Congress of Obstetricians and Gynecologists ACS American Cancer Society AEFI Adverse Event Following Immunization AHRQ Agency for Healthcare Research and Quality AIDS Acquired Immunodeficiency Syndrome AIM Association of Immunization Managers AIRA American Immunization Registry Association APhA American Pharmacists Association AITF Adult Immunization Task Force ASH Assistant Secretary for Health ASPR Assistant Secretary for Preparedness and Response ASTHO Association of State and Territorial Health Officials BARDA Biomedical Advanced Research and Development Authority (within the Office of the Assistant Secretary for Preparedness and Response or ASPR) BMGF Bill & Melinda Gates Foundation BPHC Bureau of Primary Health Care (within the Healthcare Research and Services Administration) BSL Biosafety Level CBER Center for Biologics Evaluation and Research (of the Food and Drug Administration) CICP Countermeasure Injury Compensation Program (within the Healthcare Research and Services Administration) CDC Centers for Disease Control and Prevention CISA Clinical Immunization Safety Assessment CME Continuing Medical Education credit CMS Centers for Medicare & Medicaid Services CRS Congenital Rubella Syndrome CSTS Council of State and Territorial Epidemiologists DHS U.S. Department of Homeland Security DoD U.S. Department of Defense DoJ U.S. Department of Justice DPT Diphtheria-Pertussis-Tetanus vaccine DTaP Diphtheria-Tetanus-Pertussis vaccine EHR Electronic Health Record EIND Emergency Investigational New Drug EUA Emergency Use Authorization FDA Food and Drug Administration FIC Fogarty International Center (within the National Institutes of Health) FQHC Federally Qualified Health Center FY Fiscal Year GAP Global Action Plan for Influenza Vaccines GAVI The GAVI Alliance GBS Guillain-Barré syndrome GPEI Global Polio Eradication Initiative HCP Health Care Professional or Health Care Personnel HCV Hepatitis C Virus HepA Hepatitis A HepB Hepatitis B HepC Hepatitis C HHS U.S. Department of Health and Human Services Hib Haemophilus influenza type b HIE Health Information Exchange HIV Human Immunodeficiency Virus HPV Human Papilloma Virus HRSA Health Resources and Services Administration HSV Herpes Simplex Virus ICT Information and Communication Technologies STATE OF THE NATIONAL VACCINE PLAN 2014 3 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ACRONYMS AND ABBREVIATIONS IHS Indian Health Service IIS Immunization Information Systems IIV Inactivated Influenza Vaccine IOM Institute of Medicine ISTF Immunization Safety Task Force JE Japanese Encephalitis LTC Long-Term Care MCV Meningococcal Vaccine MD Medical Doctor MenB Meningococcal serogroup B MMR Measles, Mumps, and Rubella vaccine MPH Master of Public Health MSF Médecins Sans Frontières International (Doctors Without Borders) NAIIS National Adult and Influenza Immunization Summit NAIP National Adult Immunization Plan NCIRD National Center for Immunization and Respiratory Diseases (within the Centers for Disease Control and Prevention) NFID National Foundation for Infectious Diseases NIAID National Institute of Allergy and Infectious Diseases (within the National Institutes of Health) NIH National Institutes of Health NNDSS National Notifiable Disease Surveillance System NVAC National Vaccine Advisory Committee NVPO National Vaccine Program Office OGA Office of Global Affairs ONC Office of the National Coordinator for Health Information Technology OPV Oral Polio Vaccine PAHO Pan American Health Organization PCP President’s Cancer Panel PCV Pneumococcal conjugate
Load more

Recommended publications
  • Healthcare Personnel Vaccination Recommendations1 Vaccine ­ Recommendations in Brief ­
    Healthcare Personnel Vaccination Recommendations1 Vaccine Recommendations in brief Hepatitis B Give 3-dose series (dose #1 now, #2 in 1 month, #3 approximately 5 months after #2). Give IM. Obtain anti-HBs serologic testing 1–2 months after dose #3. Influenza Give 1 dose of influenza vaccine annually. Give inactivated injectable influenza vaccine intramuscularly or live attenuated influenza vaccine (LAIV) intranasally. MMR For healthcare personnel (HCP) born in 1957 or later without serologic evidence of immunity or prior vaccination, give 2 doses of MMR, 4 weeks apart. For HCP born prior to 1957, see below. Give SC. Varicella For HCP who have no serologic proof of immunity, prior vaccination, or history of varicella disease, (chickenpox) give 2 doses of varicella vaccine, 4 weeks apart. Give SC. Tetanus, diphtheria, Give a one-time dose of Tdap as soon as feasible to all HCP who have not received Tdap previously. pertussis Give Td boosters every 10 years thereafter. Give IM. Meningococcal Give 1 dose to microbiologists who are routinely exposed to isolates of N. meningitidis. Give IM or SC. Hepatitis A, typhoid, and polio vaccines are not routinely recommended for HCP who may have on-the-job exposure to fecal material. Hepatitis B Healthcare personnel (HCP) who perform tasks that may involve exposure to of live rubella vaccine). HCP with 2 documented doses of MMR are not blood or body fluids should receive a 3-dose series of hepatitis B vaccine at recommended to be serologically tested for immunity; but if they are tested 0-, 1-, and 6-month intervals. Test for hepatitis B surface antibody (anti-HBs) and results are negative or equivocal for measles, mumps, and/or rubella, to document immunity 1–2 months after dose #3.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    9. Special Situations Updates Major revisions to this section of the best practices guidance include the timing of intramuscular administration and the timing of clotting factor deficiency replacement. Concurrent Administration of Antimicrobial Agents and Vaccines With a few exceptions, use of an antimicrobial agent does not interfere with the effectiveness of vaccination. Antibacterial agents have no effect on inactivated, recombinant subunit, or polysaccharide vaccines or toxoids. They also have no effect on response to live, attenuated vaccines, except BCG vaccines. Antimicrobial or immunosuppressive agents may interfere with the immune response to BCG and should only be used under medical supervision (for additional information, see www.merck.com/product/usa/pi_circulars/b/bcg/bcg_pi.pdf). Antiviral drugs used for treatment or prophylaxis of influenza virus infections have no effect on the response to inactivated influenza vaccine (2). However, live, attenuated influenza vaccine should not be administered until 48 hours after cessation of therapy with antiviral influenza drugs. If feasible, to avoid possible reduction in vaccine effectiveness, antiviral medication should not be administered for 14 days after LAIV administration (2). If influenza antiviral medications are administered within 2 weeks after receipt of LAIV, the LAIV dose should be repeated 48 or more hours after the last dose of zanamavir or oseltamivir. The LAIV dose should be repeated 5 days after peramivir and 17 days after baloxavir. Alternatively, persons receiving antiviral drugs within the period 2 days before to 14 days after vaccination with LAIV may be revaccinated with another approved vaccine formulation (e.g., IIV or recombinant influenza vaccine). Antiviral drugs active against herpesviruses (e.g., acyclovir or valacyclovir) might reduce the efficacy of vaccines containing live, attenuated varicella zoster virus (i.e., Varivax and ProQuad) (3,4).
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Mmrv Vaccine
    VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines.
    [Show full text]
  • SARS-Cov-2 Protein Subunit Vaccination Elicits Potent Neutralizing Antibody Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.31.228486; this version posted July 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses Marco Mandolesi1,*, Daniel J. Sheward1,2,*, , Leo Hanke1, Junjie Ma1, Pradeepa Pushparaj1, Laura Perez Vidakovics1, Changil Kim1, Karin Loré3, Xaquin Castro Dopico1, Jonathan M. Coquet1, Gerald McInerney1, Gunilla B. Karlsson Hedestam1,†, , and Ben Murrell1,†, 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa 3Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden *These authors contributed equally †These authors contributed equally The outbreak and spread of SARS-CoV-2 (Severe Acute Res- Results piratory Syndrome coronavirus 2), the cause of coronavirus dis- ease 2019 (COVID-19), is a current global health emergency and To evaluate the use and immunogenicity of recombinant a prophylactic vaccine is needed urgently. The spike glycopro- protein subunit vaccines for SARS-CoV-2 we immunized tein of SARS-CoV-2 mediates entry into host cells, and thus is a C57BL/6J mice (N=24) with either the spike ectodomain or target for neutralizing antibodies and vaccine design. Here we RBD, expressed in 293-F cells. The RBD domain was ex- show that adjuvanted protein immunization with SARS-CoV-2 pressed as an Fc-fusion protein, which was cleaved and the 1 spike trimers, stabilized in prefusion conformation , results in RBD subsequently purified by size-exclusion chromatogra- potent antibody responses in mice and rhesus macaques with phy.
    [Show full text]
  • Adult Vaccines
    What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S.
    [Show full text]
  • ALTIMMUNE, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 ☐ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-32587 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 20-2726770 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (240) 654-1450 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Boosting Our Best Shot
    NEWS FEATURE Boosting Our Best al orr a C rin Ma s by Shot ration Illust Vaccines work by training the immune system to target pathogens, but many types of shots need added substances called adjuvants to elicit a robust response. Despite the power of adjuvants, only one, called alum, is approved in the US. Charlotte Schubert looks at recent discoveries that could translate into a wider range of adjuvants and perhaps help provide future protection against diseases ranging from malaria to H1N1 ‘swine’ flu. © All rights reserved. 2009 Inc. Nature America, Max Theiler never thought it would be easy to particularly good at bumping up the immune FDA is poised to give the green light to such vanquish one of the biggest killers of his time. response. By comparison, most vaccines adjuvanted vaccines, lined up for approval in Yellow fever had already stumped a previous developed today rely on bits of microbes, such Europe, remains unclear (see sidebar). generation of microbe-hunters. And in the as short protein sequences—and they don’t For many years, researchers such as Theiler early 1900s it killed subjects who volunteered work quite so well on their own. To elicit an moved their vaccine candidates forward with for experiments in which they received bites immune response, these vaccines typically little mechanistic understanding of how they from mosquitoes, proving that the insects need a jolt from an adjuvant, a substance worked. That empirical approach is ending, transmit the disease. named from the Latin ‘adjuvans’, which says Bali Pulendran, an immunologist at the Theiler’s work was painstaking.
    [Show full text]
  • Vaccine Information for PARENTS and CAREGIVERS
    NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been
    [Show full text]
  • Lessons Learnt from Influenza A(H1N1) Vaccines Benefit-Risk Monitoring Encepp Plenary Meeting
    Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 2010 An agency of the European Union ContentsContents 1. Safety database at time of authorisation 2. Mechanisms for vaccine safety surveillance 3. What worked well 4. Areas for improvement of vaccine vigilance system 5. On-going work 2 1. Safety database at time of authorisation Pandemrix • H5N1 vaccine: 6,100 subjects – 300 children 3-9 years, 5,071 adults 18-60 years, 729 elderly >60 years • H1N1 vaccine: 130 adults 18-60 years Focetria • H5N1 vaccine: 1,496 subjects – 145 children 6-35 months, 96 children 3-8 years, 93 children 9-17 years, 989 adults 18-60 years, 173 elderly >60 years • H1N1 vaccine: none Celvapan • H5N1 vaccine: 836 subjects – 556 adults 18-60 years, 280 elderly > 60 years • H1N1 vaccine: none Safety profiles observed with H5N1 vaccines expected to be generally applicable to A/H1N13 vaccines. Limited data in children and pregnant women. European Strategy published on 5 November 2009 http://www.emea.europa.eu/pdfs/human/pandemicinfluenza/european_strategy.pdf or: EMEA website Æ Pandemic influenza website Æ Latest news 4 2. Vaccine safety surveillance Marketing Authorisation Holders • Monthly simplified Periodic Safety Update Reports (s-PSUR) • Summary of important information from spontaneous reports and analysis of safety issues in populations at risk • PASS of 9,000 subjects for each vaccine stratified by age • As soon as vaccination starts • Pregnancy registries • Creation or collaboration with existing
    [Show full text]
  • Immunization-Form.Pdf
    James Madison University Immunization Form COMMONWEALTH OF VIRGINIA LAW REQUIRES THAT THE CERTIFICATE OF IMMUNIZATION AND TB SCREENING BE COMPLETED AND SUBMITTED TO THE UNIVERSITY HEALTH CENTER. Instructions for new students: 1) Download (if .pdf does not display correctly, open the file in Adobe Reader) and print the Immunization Form and have it completed and signed by a health care professional. An official immunization record from your doctor or another school will be accepted. 2) Log into your MyJMUChart account to upload the completed and signed immunization form (or official record), as well as a copy of your health insurance card (front and back.) All uploaded forms must be in .pdf format. Immunizations must be up to date. 3) Complete the required TB Assessment and Health History for NEW students located under the “forms” tab in MyJMUChart. Due dates for undergraduate students: July 8, 2021 for Fall 2021 semester start and December 10, 2021 for Spring 2022 start. Due date for graduate students: No later than the third Friday of the first semester attending JMU. An enrollment hold and a $50 fine will be placed on your account if your immunization form and TB Screening are not deemed complete by the Health Center staff. CERTIFICATE OF IMMUNIZATION* This MUST be signed by a health care provider Name (print): _______________________________________________ Date of Birth: ______/_______/_______________ Date completed: _______/_______/_______ STUDENT ID NUMBER: __________________________ REQUIRED IMMUNIZATIONS COVID-19 (indicate which
    [Show full text]
  • Evidence Assessment STRATEGIC ADVISORY GROUP of EXPERTS (SAGE) on IMMUNIZATION Meeting 15 March 2021
    Evidence Assessment STRATEGIC ADVISORY GROUP OF EXPERTS (SAGE) ON IMMUNIZATION Meeting 15 March 2021 FOR RECOMMENDATION BY SAGE Prepared by the SAGE Working Group on COVID-19 vaccines EVIDENCE ASSESSMENT: Ad26.COV2.S COVID-19 vaccine Key evidence to inform policy recommendations on the use of Ad26.COV2.S COVID-19 vaccine Evidence retrieval • Based on WHO and Cochrane living mapping and living systematic review of Covid-19 trials (www.covid-nma.com/vaccines) Retrieved evidence Majority of data considered for policy recommendations on Ad26.COV2.S Covid-19 vaccine are published in scientific peer reviewed journals: • Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. NEJM. February 2021. DOI: 10.1056/NEJMoa2034201. Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al. • FDA briefing document Janssen Ad26.COV2.S (COVID-19) Vaccine • Ad26 platform literature: Custers et al. Vaccines based on the Ad26 platform; Vaccine 2021 Quality assessment Type of bias Randomization Deviations from Missing outcome Measurement of Selection of the Overall risk of intervention data the outcome reported results bias Working Group Low Low Low Low Low LOW judgment 1 EVIDENCE ASSESSMENT The SAGE Working Group specifically considered the following issues: 1. Trial endpoints used in comparison with other vaccines Saad Omer 2. Evidence on vaccine efficacy in the total population and in different subgroups Cristiana Toscano 3. Evidence of vaccine efficacy against asymptomatic infections, reducing severity, hospitalisations, deaths, and efficacy against virus variants of concern Annelies Wilder-Smith 4. Vaccination after SARS-CoV2 infection. 5. Evidence on vaccine safety in the total population and in different subgroups Sonali Kochhar 6.
    [Show full text]